Home > News > Headline News

News

Please Note

Some news stories may require you to register or sign in.  MedPage, for example, has an easy and free subscription form that only needs to be completed once--well worth the effort to access their timely and important articles.

Click on title to read the full article.

Seattle Genetics Initiates Phase 1 Trial of ADC Candidate, SGN-LIV1A,

October 27, 2013

The target expression in breast cancer, preclinical antitumor activity, and need for novel therapeutic options for advanced breast cancer patients all support the clinical evaluation of SGN-LIV1A.

POINT-COUNTERPOINT: In Keynote Lectures, George Sledge and Monica Morrow Predict How Breast Cancer Will Be Treated in Next Decad

October 25, 2013

By Oncology Times

SAN FRANCISCO—It was with rapt attention that the audience here at the Breast Cancer Symposium listened to the two keynote lectures. The two noted experts were attempting to answer the question “How Will We Be Treating Breast Cancer in Five to 10 Years?”

George Sledge, MD, Professor and Chief of the Division of Oncology at Stanford University School of Medicine, took on the role of futurist for Medical Oncology.

Monica Morrow, MD, Chief of the Breast Service in the Department of Surgery and Chair of Clinical Oncology at Memorial Sloan-Kettering Cancer Center, gave her predictions from the viewpoint of Surgical Oncology.

New models of drug-resistant breast cancer hint at better treatments

October 21, 2013

By Genome Institute of Washington University

Researchers at The Genome Institute and Washington University School of Medicine have shown that human breast tumors transplanted into mice are excellent models of metastatic cancer and could be valuable tools in the search for better treatments.

UM researchers take new view in understanding metastatic breast cancer

October 21, 2013

By Scott Dance, Baltimore Sun

Focus on 'microtentacles' aims to prevent disease's ability to spread

Breast cancer kills when rogue tumor cells spread through the bloodstream, squeezing through microscopic gaps to inundate organs until they fail. But what if that spread could be prevented, the cells left free-floating to be crushed in capillaries or to self-destruct instead?

A team of researchers at the University of Maryland School of Medicine, joined by entrepreneurs and other academics, has been exploring that question for nearly a decade. What they have found challenges the basis for most breast cancer research and treatment, which focus on preventing tumor cells from multiplying.

Rugo Offers Window Into Evolving Views of ER-Positive Disease

October 15, 2013

By Onc Live

Research efforts are under way to improve the efficacy of hormone therapy in the management of advanced estrogen receptor-positive (ER) breast cancer, including new strategies for targeting the PI3K/ mTOR pathway.

First Generic Version of Capecitabine Gains FDA Approval

October 14, 2013

By OncLive

The FDA has approved the first generic formulation of capecitabine (Xeloda), an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer (mCRC) and metastatic breast cancer (MBC).

A roundup of FDA oncology news from September 2013

October 5, 2013

By Oncology Nurse Advisor

After winning accelerated approval from the U.S. FDA (FDA), Perjeta (pertuzumab) has become the first FDA-approved drug for the neoadjuvant treatment of breast cancer. The recombinant humanized monoclonal antibody was first approved in 2012 for the treatment of metastatic HER2-positive breast cancer.

Breast cancer spread: clues found in molecular switch

October 1, 2013

By Medical News Today

We have pinpointed the binding site that can cause increased spreading of breast cancer cells and thus the development of metastases.

Genentech’s Kadcyla Helped People With Advanced HER2-Positive Breast Cancer Live Longer Without Their Disease Worsening in New P

September 27, 2013

By Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that Kadcyla® (ado-trastuzumab emtansine) significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival [PFS], a co-primary endpoint) compared to people who received a treatment of their physician’s choice in an open-label Phase III study called TH3RESA.

New knowledge on molecular mechanisms behind breast cancer

September 26, 2013

Researchers at University of Copenhagen have gained more insight into the molecular mechanisms of importance for, for example, cancer cell growth and metastasis.

‹ First  < 2 3 4 5 6 >  Last ›